Point72 (DIFC)’s Cue Biopharma CUE Stock Holding History

Point72 (DIFC)’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2	Closed	-$72	–	1737
2024 Q4	$72	Hold	2	–	–	﹤0.01%	1459
2024 Q3	$44	Sell	2 -382	-99%	-$8.27K	﹤0.01%	1374
2024 Q2	$14.3K	Buy	+384	New	+$19K	﹤0.01%	1284

Other funds holding CUE

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Point72 (DIFC)'s CUE Position: Q1 2025 in Review

Point72 (DIFC) sold out of Cue Biopharma (CUE) in Q1 2025, closing a stake of 2 shares — an estimated $72 sold.

Point72 (DIFC) first reported a position in CUE in Q2 2024 and held it in 3 quarters. The position peaked at $14.3K in Q2 2024. 49 funds tracked by Wall St. Rank hold CUE as of Q1 2025.

Point72 (DIFC) reported no remaining Cue Biopharma position as of Q1 2025 after selling out during the quarter.
Point72 (DIFC) sold 2 Cue Biopharma shares in Q1 2025, an estimated $72.
Point72 (DIFC) first reported a position in Cue Biopharma in Q2 2024 and held it in 3 quarters.
Point72 (DIFC)'s Cue Biopharma position peaked at $14.3K in Q2 2024.
49 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2025.

Based on Point72 (DIFC)'s 13F filing for Q1 2025, filed 15 May 2025.